Exemestane aromatase inhibitors

Description Results NMA

Clinical benefit (assessable) 1.02 [0.80; 1.31]

Objective response (assessable) 1.11 [0.60; 2.05]

diarrhoea 0.86 [0.37; 1.95]

nausea 1.15 [0.68; 1.96]

progression-free survival (reported or calculated) 1.04 [0.52; 2.07]

Objective response (randomised) 1.08 [0.58; 2.01]

Clinical benefit (randomised) 1.00 [0.77; 1.29]

hot flushes 1.29 [0.83; 2.02]

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Objective response (assessable) 0.39 [0.21; 0.74]

Objective response (randomised) 0.41 [0.22; 0.79]

Clinical benefit (assessable) 0.70 [0.49; 1.00]

nausea 0.63 [0.36; 1.13]

Clinical benefit (randomised) 0.74 [0.51; 1.07]

arthralgia 1.74 [0.69; 4.42]

hot flushes 0.79 [0.52; 1.18]

exemestane (n=-9)

vs.

tamoxifen (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vomiting 3.72 [1.03; 13.43]

nausea 1.84 [1.08; 3.15]

hot flushes 2.51 [1.51; 4.17]

Clinical benefit (assessable) 0.93 [0.77; 1.13]

Objective response (assessable) 0.84 [0.59; 1.19]

overall survival (reported or calculated) 0.85 [0.49; 1.48]

progression-free survival (reported or calculated) 0.82 [0.46; 1.45]

Objective response (randomised) 0.83 [0.58; 1.18]

Clinical benefit (randomised) 0.92 [0.76; 1.12]

rash ∞ [NaN; ∞]

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: